Curculigoside attenuates myocardial ischemia-reperfusion injury by inhibiting the opening of the mitochondrial permeability transition pore

Abstract

The aim of the present study was to determine whether curculigoside protects against myocardial ischemia-reperfusion injury (MIRI) and to investigate the underlying mechanisms. An in vitro model of hypoxia/reoxygenation (H/R) was established by culturing H9c2 cells under hypoxic conditions for 12 h, followed by reoxygenation for 1 h. Cell Counting kit-8 and lactate dehydrogenase (LDH) assays were subsequently used to examine cell viability and the degree of cell injury. In addition, isolated rat hearts were subjected to 30 min of ischemia followed by 1 h of reperfusion to establish a MIRI model. Triphenyltetrazolium chloride (TTC) staining was performed to measure the infarct size. Furthermore, TUNEL staining and flow cytometry were employed to evaluate cell apoptosis. The opening of the mitochondrial permeability transition pore (MPTP) and changes in the mitochondrial membrane potential (ΔΨm) were assessed. Reverse transcription-quantitative PCR and western blot analysis were performed to investigate the expression levels of mitochondrial apoptosis-related proteins. Curculigoside pre-treatment significantly improved cell viability, decreased cell apoptosis and LDH activity, and reduced the infarct size and myocardial apoptosis in vitro and ex vivo, respectively. Moreover, curculigoside markedly inhibited MPTP opening and preserved the ΔΨm. In addition, curculigoside significantly decreased the expression of cytochrome c, apoptotic protease activating factor-1, cleaved caspase-9 and cleaved caspase-3. Notably, atractyloside, a known MPTP opener, abrogated the protective effects of curculigoside. On the whole, the present study demonstrated that curculigoside protected against MIRI, potentially by decreasing the levels of mitochondria-mediated apoptosis via the inhibition of MPTP opening. Therefore, the results obtained in the present study may provide the theoretical basis for the future clinical application of curculigoside.

Introduction

Acute myocardial infarction (AMI) is a major cause of mortality worldwide and the incidence of AMI has increased in China in recent years. Revascularization to restore blood flow is currently the most effective treatment for AMI (1). However, while early reperfusion is effective in decreasing mortality, the perfusion of previously ischemic myocardial tissue results in a second wave of injury, which is referred to as myocardial ischemia-reperfusion injury (MIRI) (2,3). MIRI may lead to severe adverse events, including acute left ventricular failure and malignant arrhythmia (4). Therefore, preventing MIRI in the early stages of AMI may improve patient prognosis.

The mitochondrial permeability transition pore (MPTP), which is located in the inner membrane, plays an important role in apoptosis (5). Following ischemia, reperfusion may result in the generation of reactive oxygen species and Ca²⁺ influx, which may lead to the opening of the MPTP (6,7). The opening of the MPTP, which is known as the mitochondrial permeability transition, decreases the inner mitochondrial membrane potential (ΔΨm). It also leads to the release of cytochrome c into the cytoplasm and activates caspase, resulting in mitochondrial dysfunction and swelling, eventually leading to apoptosis (8–11). Previous studies have demonstrated that the inhibition of the opening of the MPTP with an inhibitor, such as cyclosporin A, may alleviate MIRI (12,13), while promoting MPTP opening, with for example, atractyloside, may aggravate MIRI (14). Therefore, the MPTP may serve as an important target for modulating MIRI.

Certain natural compounds are known to exert pharmacological actions and are generally well-tolerated by the human body. Curculigoside, extracted from Curculigo orchioides Gaertn, is a phenolic glycoside antioxidant that exerts anti-inflammatory and antitumor effects (15–17). Curculigoside has been demonstrated to inhibit H₂O₂-induced oxidative stress in human umbilical vein endothelial cells (18). Furthermore, several studies have reported that curculigoside attenuates experimental cerebral ischemia injury in vitro and ex vivo (19–21). However, whether curculigoside exerts a cardioprotective effect following I/R injury remains unclear.

The aim of the present study was to determine whether curculigoside exerts cardioprotective effects following I/R or H/R injury in vitro and ex vivo and to investigate whether the underlying mechanisms involve the inhibition of MPTP opening.

Materials and methods

Drugs

Curculigoside (CAS no. 85643-19-2; formula, C₂₂H₂₆O₁₁; the chemical structure of curculigoside can be found at: http://www.chemfaces.com/natural/Curculigoside-CFN97419.html) and atractyloside were purchased from ChemFaces^® and Nantong Feiyu Biological Technology Co. Ltd., respectively. Both drugs were dissolved in 1% dimethyl sulfoxide (DMSO; Solarbio Science & Technology Co.) and stored at −20°C until further use.

Cell culture

H9c2 rat cardiomyocytes were purchased from the Cell Bank of the Chinese Academy of Sciences. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C in a humidified atmosphere containing 5% CO₂.

Induction of the H/R model in vitro

Upon reaching 80–90% confluence, the H9c2 cells were pre-treated with curculigoside (5, 10 and 15 μM) or the equivalent volume of 1% DMSO for 8 h. The spent DMEM was replaced with glucose- and FBS-free Earle’s medium in all groups, except for the control group. Cells were subsequently incubated in a tri-gas chamber containing 95% (v/v) N₂, 5% (v/v) CO₂ and 5% O₂ at 37°C for 12 h to induce hypoxia. Earle’s medium was replaced with DMEM supplemented with 10% FBS and the cells were incubated at 37°C and 5% CO₂ for 1 h to allow reoxygenation.

Cell experiment protocol

H9c2 cells were divided into 6 groups as follows: i) The control group; ii) the hypoxia/reoxygenation group (H/R); iii) the vehicle group; iv) the 5 μM curculigoside-treated group; v) the 10 μM curculigoside-treated group; and vi) the 15 μM curculigoside-treated group. Based on the results obtained, curculigoside was used at a concentration of 10 μM in subsequent experiments. H9c2 cells were subsequently divided into 5 groups as follows: i) The control group; ii) the H/R group; iii) the vehicle group; iv) the 10 μM curculigoside-treated group; v) the combined treatment group (10 μM curculigoside and 20 μM atractyloside). The curculigoside-treated and combined treatment groups were treated with curculigoside and curculigoside and atractyloside, respectively, for 8 h prior to H/R.

Assessment of cell proliferation

The proliferation of the H9c2 cells was assessed using a Cell Counting kit-8 (BD Biosciences) assay, according to the manufacturer’s protocol. The H9c2 cells (3×10³ cells/well) were cultured in 96-well plates. Following treatment, 10 μl CCK-8 solution were added to each well and incubated for 1 h at 37°C in a 5% CO₂ incubator. The optical density was measured at a wavelength of 490 nm using a microplate reader (Biotek Instruments, Inc.).

Assessment of lactate dehydrogenase (LDH) activity

LDH activity was assessed to evaluate the cytoprotective effects of curculigoside. An LDH assay (Nanjing Jiancheng Bioengineering Institute) was performed according to the manufacturer’s instructions. The optical density was measured at a wavelength of 450 nm using a microplate reader (Biotek Instruments, Inc.) and was used to calculate the concentration of LDH.

Assessment of H9c2 cell apoptosis

The apoptotic rate of the H9c2 cells was evaluated by flow cytometry using an Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) kit (BD Biosciences). Cells in 6-well plates were trypsinized and washed twice in ice-cold PBS. Cells were suspended in binding buffer and 5 μl Annexin V-FITC and 5 μl PI were added to each sample. The cells were incubated at room temperature in the dark for 15 min and analyzed using a flow cytometer (BD Biosciences).

Assessment of ΔΨm

The change in ΔΨm was measured by rhodamine 123 staining following the manufacturer’s protocol (Beyotime Institute of Biotechnology). Cell apoptosis leads to a decrease in ΔΨm and a reduction in the fluorescence intensity in cells. The H9c2 cells were incubated with rhodamine 123 for 30 min at 37°C in the dark. Cells were visualized by fluorescence microscopy (IX73, Olympus) and the staining was analyzed using Image-Pro software.

Assessment of MPTP opening

MPTP opening was determined using the CaCl₂-induced method (22). Mitochondria were isolated from the H9c2 cells using the Mitochondrial Extract kit (BestBio Co.), according to the manufacturer’s instructions. The sensitivity of MPTP opening to Ca²⁺ was determined using the Purified Mitochondrial Membrane Pore Channel Colorimetric Assay kit (Shanghai Genmed Pharmaceutical Technology Co., Ltd.), according to the manufacturer’s protocol.

Animals and animal care

Male Wistar rats (age, 8 weeks; weight, 300±30 g) were purchased from Liaoning Changsheng Biotechnology Co. and housed in environmentally-controlled conditions (temperature, 22±2°C; relative humidity, 60±5%; 12-h light/dark cycles). All rats were allowed to acclimatize to their environment prior to the experiments and fed a standard diet. Food and bedding were changed for the rats, and the health of the animals was monitored every other day. The present study was approved by the Ethics Committee of China Medical University and procedures for animals handling and care adhered to the Guide for the Care and Use of Laboratory Animals (23).

Induction of the ischemia-reperfusion group (I/R) model

Krebs-Henseleit (K-H) buffer (0.15 mol/l NaCl, 0.006 mol/l KCl, 0.002 mol/l CaCl₂, 0.002 mol/l NaHCO₃ and 0.011 mol/l glucose) was prepared and the pH was adjusted to 7.35–7.45 by the addition of NaOH. The rats were anesthetized by an intraperitoneal injection of 30 mg/kg pentobarbital sodium. An incision was made into the thoracic cavity and the heart was rapidly removed and placed in ice-cold heparinized K-H buffer with continuous oxygenation (oxygen flow rate, 3 l/min). The heart connective tissue was resected to expose the aorta, which was subsequently connected to a Langendorff system. The isolated hearts were retrogradely perfused with K-H buffer containing 95% O₂ and 5% CO₂ for 15 min at 37°C and at a constant pressure of 76 mmHg. Rat hearts were subjected to global ischemia for 30 min, followed by 60 min of reperfusion to generate the MIRI model as described in a previous study by the authors (24). All rats used in this study (total, 165 rats) were subjected to euthanasia. As for the details of euthanasia, each of the rats was anesthetized in an isolated room individually by intraperitoneal injection of pentobarbital sodium at a dose of 30 mg/kg. After confirming that the rat was completely anesthetized and unconscious by determining whether the rats exhibited nerve reflexes or not, the chest of the rat was opened, the aorta was disconnected and the heart was rapidly isolated to induce the permanent cessation of circulation. The experiment described herein is an acute, non-survival experiment. Euthanasia was achieved by exsanguination during the harvesting of the heart as previously described (25).

Animal experiment protocol

The rats were randomly divided into 6 groups (n=15 rats per group) as follows: i) The control group; ii) the I/R group; iii) the vehicle group; iv) the 5 mg/kg curculigoside-treated group; v) the 10 mg/kg curculigoside-treated group; and vi) the 15 mg/kg curculigoside-treated group. Prior to isolation of the hearts, the rats in the curculigoside-treated groups received a daily intraperitoneal injection of curculigoside for 7 days. The animals in the vehicle group received the equivalent volume of 1% DMSO.

Based on the results obtained, 10 mg/kg curculigoside was selected for further experimentation. The rats were randomly divided into 5 groups (n=15 rats per group) as follows: i) The control group; ii) the I/R group; iii) the vehicle group; iv) the 10 mg/kg curculigoside-treated group; v) the combined treatment group (10 mg/kg curculigoside and 5 mg/kg atractyloside). Similar to the curculigoside-treated group, the animals in the combined treatment group received a daily intraperitoneal injection of curculigoside and atractyloside for 7 days prior to surgery.

Assessment of infarct size

Triphenyltetrazolium chloride (TTC) staining was performed to quantify the infarct size in myocardial tissues. The heart was removed and the left ventricular tissue was frozen at −70°C and subsequently cut into 2-mm-thick sections. The sections were incubated with 1% TTC (Solarbio Science & Technology Co.) at 37°C for 30 min at 37°C in the dark. Images of the staining were acquired using a digital camera (EOS 90D, Canon) and the staining was quantified by ImageJ2x software.

Assessment of myocardial morphological changes

Hearts were removed from the Langendorff system after 1 h of reperfusion and fixed in 4% paraformaldehyde overnight at 4°C. Following dehydration with ethanol, the left ventricular tissue was embedded in paraffin and cut into 5-μm-sections using a rotary microtome. Following dewaxing and rehydration, the sections were immersed in hematoxylin solution for 5 min, 1% hydrochloric acid alcohol for 3 sec, and eosin solution for 3 min at room temperature for staining. Myocardial morphological characteristics were subsequently observed using a light microscope (CX23, Olympus).

Assessment of myocardial apoptosis

Terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling (TUNEL) staining was performed to assess myocardial apoptosis using the In Situ Cell Death Detection kit (Roche Diagnostics), according to the manufacturer’s instructions. TUNEL-positive cells were stained dark grey and were visible under a light microscope (CX23, Olympus).

Assessment of protein expression

Total protein was extracted from myocardial tissue and H9c2 cells using radioimmunoprecipitation assay buffer and protease inhibitors. Total protein was quantified using a bicinchoninic acid assay and 30 μg protein/lane was separated via SDS-PAGE on 10% gels. The separated proteins were subsequently transferred onto polyvinylidene difluoride membranes and blocked for 1 h at room temperature with 5% skim milk dissolved in TBST. The membranes were then incubated with primary antibodies against B-cell lymphoma 2 (Bcl-2; 1:500; Wan Biotechnology; cat. no. WL01556), Bcl-2-associated X protein (Bax; 1:500; Wan Biotechnology; cat. no. WL01637), apoptotic protease activating factor-1 (APAF-1; 1:1,000; Proteintech; cat. no. 21093-1-AP), cytochrome c (1:1,000; Proteintech; cat. no. 66264-1-Ig), cleaved caspase-9 (1:500; Wan Biotechnology; cat. no. 66264-1-Ig), cleaved caspase-3 (1:500; Wan Biotechnology; cat. no. WL01992), β-actin (1:500; Wan Biotechnology; cat. no. WL01372) overnight at 4°C. Following incubation with the primary antibodies, the membranes were incubated with horseradish peroxidase-labeled anti-mouse and anti-rabbit secondary antibodies (both 1:4,000; EarthOx Life Sciences; cat. no. E030110-02 and E030120-02) for 0.5 h at room temperature. Protein bands were visualized using enhanced chemiluminescence substrates. Protein expression was quantified using ImageJ software (version 1.51).

Assessment of mRNA expression

Total RNA was extracted from myocardial tissue and H9C2 cells using TRIzol^® reagent (Solarbio Science & Technology Co.), according to the manufacturer’s protocol. The concentration and the purity of the RNA samples were analyzed using the Nanodrop 2000 System (Thermo Fisher Scientific, Inc.). Total RNA was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara Bio), according to the manufacturer’s protocol. The following temperature protocol was used: 37°C for 15 min, 85°C for 5 sec and cooling down to 4°C. qPCR was subsequently performed using the SYBR Premix Ex Taq II (Takara Bio), according to the manufacturer’s instructions. The primer pairs used for qPCR were designed by Biotechnology Co., Ltd. and are presented in Table I. The following thermocycling conditions were used: i) Step 1, 5 min at 95°C; ii) step 2, 8 cycles at 95°C for 30 sec, at 60°C for 45 sec, at 72°C for 20 sec; iii) step 3, 35 cycles at 95°C for 30 sec, at 56°C for 45 sec, at 72°C for 20 sec; and iv) step 4, 1 min at 95°C, 30 sec at 55°C, 30 sec at 95°C. GAPDH was used as the internal reference gene. Target gene mRNA levels were quantified using the 2^−ΔΔCq method (26).

Table I.

Primer sequences used for quantitative PCR.

Primers	Primer sequences (5′-3′)
Cytochrome c	Forward: AGGGTGTCGCCTCAAACCTA
Cytochrome c	Reverse: ACTGAAGCACGGGTGAGTCT
APAF1	Forward: CAAGGACACAGACGGTGGAA
APAF1	Reverse: TGAATCGCACTGACCAGCTT
Caspase-9	Forward: CAGGTGGAGGTCAGGTGTGA
Caspase-9	Reverse: TCCGTGAGAGAGGATGACCA
Caspase-3	Forward: CCATCCTTCAGTGGTGGACA
Caspase-3	Reverse: TTGAGGCTGCTGCATAATCG
Bax	Forward: GGCGATGAACTGGACAACAA
Bax	Reverse: CAGTTGAAGTTGCCGTCTGC
Bcl-2	Forward: CACGGTGGTGGAGGAACTCT
Bcl-2	Reverse: TCCACAGAGCGATGTTGTCC

Statistical analysis

To ensure the consistency and repeatability of the results, individual experiments were performed in triplicate. The experimental results are presented as the means ± standard deviation. One-way analysis of variance followed by Tukey’s multiple comparison test was used to compare the groups. P<0.05 was considered to indicate a statistically significant difference. All data were analyzed using SPSS software (version 20.0; IBM Corp.).

Results

Curculigoside inhibits H/R injury in H9c2 cells in vitro

Following H/R injury, the proliferation of the H9c2 cells was significantly decreased. Curculigoside pre-treatment significantly increased cell proliferation following H/R injury. The protective effects of 10 and 15 μM curculigoside on cell viability were significantly more prominent compared with those of 5 μM curculigoside. No significant differences were observed between the 10 and 15 μM curculigoside groups (Fig. 1A). The results of LDH assay revealed that LDH activity in the H/R group was significantly increased compared with that in the control group. The activity of LDH was significantly decreased following curculigoside pre-treatment. LDH activity in the 10 and 15 μM curculigoside-treated groups was significantly lower compared with that in the 5 μM curculigoside-treated group. However, there was no significant difference in LDH activity between the 10 and 15 μM curculigoside-treated groups (Fig. 1B). Therefore, the concentration of 10 μM curculigoside was selected for use in subsequent experiments.

Figure 1.

Effect of curculigoside on H/R injury in vitro. (A) H9c2 cell proliferation was measured using the Cell Counting kit-8 assay. (B) LDH activity was determined by a LDH assay. ^**P<0.05 vs. the control group, ^*P<0.05 vs. the H/R group, ^#P<0.05 vs. the 5 μM curculigoside-treated group. H/R, hypoxia/reoxygenation; LDH, lactate dehydrogenase; Cur, curculigoside.

Curculigoside decreases H9c2 cell apoptosis and inhibits the decrease in ΔΨm

Following rhodamine 123 staining, the florescence intensity was significantly increased in the H9c2 cells in the curculigoside-treated group compared with the H/R group, demonstrating that curculigoside pre-treatment effectively prevented the decrease in ΔΨm and maintained a high ΔΨm. On the other hand, the H/R group exhibited a loss in ΔΨm (Fig. 2A). Flow cytometric analysis revealed that following H/R injury, apoptosis was significantly increased in the untreated H9c2 cells compared with the control group. Furthermore, pre-treatment with curculigoside significantly inhibited H9c2 cell apoptosis following H/R compared with the H/R group (Fig. 2B).

Figure 2.

Curculigoside inhibits H9c2 cell apoptosis and preserves ΔΨm. (A) H9c2 cell apoptosis was assessed by flow cytometry. (B) The change in ΔΨm was measured by rhodamine 123 staining. ^**P<0.05 vs. the control group ^*P<0.05 vs. the H/R group, ^#P<0.05 vs. the curculigoside-treated group. ΔΨm, mitochondrial membrane potential; H/R, hypoxia/reoxygenation; Cur, curculigoside; ATR, atractyloside.

Curculigoside inhibits mitochondrial-mediated apoptosis

RT-qPCR analysis revealed that H/R injury significantly upregulated the mRNA expression of cytochrome c, APAF-1, caspase-9 and caspase-3 in the H9c2 cells compared with the control group in vitro. Curculigoside pre-treatment significantly attenuated the increased mRNA expression of cytochrome c, APAF-1, caspase-9 and caspase-3 in vitro (Fig. 3A). Consistent with the changes observed in mRNA expression, western blot analysis revealed that the protein expression of the aforementioned proteins in the H/R group was significantly increased compared with the control group and treatment with curculigoside prior to H/R injury significantly attenuated these increased expression levels (Fig. 3B).

Figure 3.

Curculigoside reduces the expression of cytochrome c, APAF-1, caspase-9 and caspase-3 at the gene and protein levels in vitro. (A) The mRNA expression of cytochrome c, APAF-1, caspase-9 and caspase-3 was determined by RT-qPCR. (B) The protein expression of cytochrome c, APAF-1, cleaved caspase-9 and cleaved caspase-3 was evaluated by western blot analysis. ^**P<0.05 vs. the control group, ^*P<0.05 vs. the H/R group, ^#P<0.05 vs. the curculigoside-treated group. APAF-1, apoptotic protease activating factor-1; H/R, hypoxia/re-oxygenation; Cur, curculigoside; ATR, atractyloside.

Curculigoside inhibits the opening of the MPTP

The results revealed that the sensitivity of MPTP opening to Ca²⁺ was significantly increased in the H/R group as compared with the control group, meanwhile, pre-treatment with curculigoside significantly decreased the sensitivity of MPTP opening to Ca²⁺ compared with the H/R group, indicating that curculigoside inhibited MPTP opening following H/R injury (Fig. 4).

Figure 4.

Effect of curculigoside on MPTP opening. (A) MPTP opening was induced by CaCl₂. (B) Statistical analysis for MPTP opening. Minimum optical density (min OD) represents the OD value recorded at the end of the experiment (10 min); maximum optical density (max OD) represents the OD value recorded at the onset of the experiment (0 min). Min/max OD is negatively associated with the extent of MPTP opening. ^**P<0.05 vs. the control group, ^*P<0.05 vs. the H/R group, ^#P<0.05 vs. the curculigoside-treated group. MPTP, mitochondrial permeability transition pore; H/R, hypoxia/reoxygenation; Cur, curculigoside; ATR, atractyloside.

Curculigoside regulates the expression of Bax and Bcl-2 at the gene and protein levels

RT-qPCR analysis indicated that H/R injury significantly upregulated the mRNA expression of Bax, downregulated Bcl-2 expression and decreased the ratio of Bcl-2/Bax compared with the control group. Curculigoside treatment significantly attenuated the changes in mRNA expression and increased the ratio of Bcl-2/Bax (Fig. 5A). Similarly, western blot analysis revealed that the protein expression levels of Bax and Bcl-2 were significantly increased and decreased, respectively, in the H/R group compared with the control group. Pre-treatment with curculigoside significantly attenuated the increased protein expression of Bax, the decreased protein expression of Bcl-2 and the decreased ratio of Bcl-2/Bax (Fig. 5B).

Figure 5.

Curculigoside regulates the expression of Bax and Bcl-2 at the gene and protein levels. (A) The mRNA expression of Bax and Bcl-2 was measured by reverse transcription-quantitative PCR. (B) The protein expression of Bax and Bcl-2 was analyzed by western blot analysis. ^**P<0.05 vs. the control group, ^*P<0.05 vs. the H/R group, ^#P<0.05 vs. the curculigoside-treated group. Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; H/R, hypoxia/reoxygenation; Cur, curculigoside; ATR, atractyloside.

Curculigoside attenuates I/R-induced myocardial injury ex vivo

In order to examine the potential cardioprotective effects of curculigoside, rat hearts were isolated and subjected to I/R with or without pre-treatment with 5, 10 and 15 mg/kg curculigoside. Curculigoside pre-treatment significantly decreased the infarct size compared with the I/R group. Furthermore, the infarct size was decreased in the 10 and 15 mg/kg curculigoside-treated groups compared with the 5 mg/kg curculigoside-treated group. However, there was no statistically significant difference between the infarct sizes in the 10 and 15 mg/kg curculigoside-treated groups (Fig. 6A). H&E staining revealed that the myocardial fibers in the control group were of a normal size and highly aligned. In the I/R group, the myocardial fibers were loosely and irregularly arranged and inflammatory cell infiltration and myocardial cell edema were observed. However, these pathological changes were less pronounced in the curculigoside-treated groups, particularly in the 10 mg/kg curculigoside-treated group (Fig. 6B). Accordingly, 10 mg/kg curculigoside was selected as the optimal dose and was used for subsequent experimentation.

Figure 6.

Effect of curculigoside on I/R injury ex vivo. (A) Myocardial infarct size was evaluated by triphenyltetrazolium chloride staining. (B) The pathological characteristics in the myocardium were assessed by H&E staining. n=5–6 per group. ^**P<0.05 vs. the control group, ^*P<0.05 vs. the I/R group, ^#P<0.05 vs. the 5 mg/kg curculigoside-treated group. I/R, ischemia/reperfusion; Cur, curculigoside.

Curculigoside inhibits myocardial cell apoptosis and decreases the expression of cytochrome c, APAF-1, caspase-9 and caspase-3 at the gene and protein levels ex vivo

TUNEL staining revealed that myocardial apoptosis following I/R injury was significantly decreased by pre-treatment with curculigoside (Fig. 7). RT-qPCR analysis revealed that I/R injury significantly upregulated the mRNA expression of cytochrome c, APAF-1, caspase-9 and caspase-3 compared with the control group ex vivo. Furthermore, curculigoside pre-treatment significantly attenuated the increased mRNA expression of the aforementioned proteins ex vivo (Fig. 8A). Additionally, western blot analysis revealed that the expression of these proteins in the I/R group was significantly upregulated compared with the control group. Curculigoside treatment prior to I/R injury significantly decreased the upregulated protein expression of cytochrome c, APAF-1, cleaved caspase-9 and cleaved caspase-3 (Fig. 8B).

Figure 7.

Curculigoside attenuates myocardial apoptosis ex vivo. Myocardial apoptosis was assessed by terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling staining. n=6 per group. ^**P<0.05 vs. the control group, ^*P<0.05 vs. the H/R group, ^#P<0.05 vs. the curculigoside-treated group. I/R, ischemia/reperfusion; Cur, curculigoside; ATR, atractyloside pretreatment group.

Figure 8.

Curculigoside downregulates the protein expression of cytochrome c, APAF-1, caspase-9 and caspase-3 at the gene and protein levels ex vivo. (A) The mRNA expression of cytochrome c, APAF-1, caspase-9 and caspase-3 was evaluated by reverse-transcription quantitative PCR. (B) The protein expression of cytochrome c, APAF-1, cleaved caspase-9 and cleaved caspase-3 was examined by western blot analysis. n=6. ^**P<0.05 vs. the control group, ^*P<0.05 vs. the H/R group, ^#P<0.05 vs. the curculigoside-treated group. APAF-1, apoptotic protease activating factor-1; I/R, ischemia/reperfusion; Cur, curculigoside; ATR, atractyloside.

Atractyloside abrogates the cardioprotective effects of curculigoside following I/R or H/R injury

In order to investigate whether curculigoside exerts cardioprotective effects following I/R or H/R injury by inhibiting the opening of the MPTP, the effects of atractyloside, a known MPTP opener, were examined. Apoptosis was significantly increased in the myocardium ex vivo and in H9c2 cells in vitro in the combination treatment group compared with the curculigoside-treated group (Figs. 2B and 7). Furthermore, the effects of the combination treatment on mitochondrial-mediated apoptosis were investigated. The cardioprotective effects of curculigoside following I/R or H/R injury were attenuated by atractyloside, and this resulted in decreased ΔΨm, the upregulated expression of cytochrome c, APAF-1, cleaved caspase-9 and cleaved caspase-3, increased MPTP opening, the decreased expression of Bcl-2 and the increased expression of Bax (Figs. 2A, 3A and B, 4, 5A and B, and 8A and B).

Discussion

MIRI occurs in a number of heart diseases, and while several therapeutic strategies have been proposed, there is currently no standard treatment protocol. Curculigo orchioides Gaertn is a traditional herb listed in Pharmacopeia of China (2015 edition) (27), which has been used to enhance kidney yang, strengthen bones and muscles, and alleviate coldness and wetness in the body in China for many centuries (28). A recent study also reported that the extracts from the rhizomes of the plant Curculigo orchioides Gaertnits exhibited potent antioxidant activities (29). Curculigoside is a major active constituent of Curculigo orchioides Gaertn and a number of previously published studies have revealed that curculigoside inhibits oxidative damage and I/R injury in mouse cortical neurons, rat calvarial osteoblasts and human umbilical vein endothelial cells (18,30,31). Thus, it was hypothesized that curculigoside may exert protective effects against MIRI. As expected, the results of the present study demonstrated that curculigoside attenuated MIRI in a dose-dependent manner in vitro and ex vivo. To the best of the authors’ knowledge, the present study was the first to reveal the cardioprotective effects of curculigoside on MIRI. These findings suggest that curculigoside may have a potential use for the prevention of MIRI.

Curculigoside has been demonstrated to exhibit a protective effect in nerve tissue following oxidative stress by inhibiting mitochondria-mediated apoptosis (32). Furthermore, mitochondrial-mediated apoptosis has previously been implicated in MIRI (33,34). Mounting evidence has demonstrated that MPTP plays an important role in modulating the mitochondrial apoptotic pathway, as MPTP opening releases cytochrome c and APAF-1, activates caspase-9 and caspase-3, and ultimately induces apoptosis (35,36). A previous study revealed that MPTP opening played an important role during the course of cardiac I/R injury (37). Therefore, the present study investigated whether curculigoside exerted cardioprotective effects by inhibiting MPTP opening.

In the present study, the sensitivity of the MPTP to Ca²⁺ increased and ΔΨm decreased in H9c2 cells following H/R injury. This resulted in MPTP opening, the increased expression of apoptosis-associated proteins and cardiomyocyte apoptosis (38). A decrease in ΔΨm and an increased sensitivity of MPTP to Ca²⁺ are key features of mitochondrial-mediated apoptosis (39–41). In the present study, following curculigoside pre-treatment, the sensitivity of MPTP to Ca²⁺ and the loss in ΔΨm were decreased, suggesting the inhibition of MPTP opening, and the expression of apoptosis-associated proteins and cardiomyocyte apoptosis were decreased. Atractyloside, a known MPTP opener, abrogated the inhibitory effects of curculigoside on the decreased expression of apoptosis-associated proteins and myocardial apoptosis. The results of the present study indicated that curculigoside targeted the MPTP and protected the rat myocardium and H9c2 cells against I/R or H/R injury by inhibiting MPTP opening.

Previous studies have revealed that Bax and Bcl-2 are key upstream proteins in the regulation of MPTP opening (42,43). Bax binds to voltage dependent anion channels (VDAC) and leads to MPTP opening (44). However, Bcl-2 inhibits the binding of Bax to VDAC and p53 to peptidylprolyl isomerase D, and decreases MPTP opening (44,45). Therefore, the ratio of Bax/Bcl-2 regulates MPTP opening (46). The present study revealed that curculigoside increased the expression of Bcl-2, and decreased the expression of Bax, therefore increasing the Bcl-2/Bax ratio. This suggested that curculigoside inhibited MPTP opening by decreasing the Bax/Bcl-2 ratio.

The present study had two important limitations. Firstly, the isolated rat heart model lacks humoral and neural regulation and does not accurately represent the physiological progression of MIRI in situ. Future studies are required to investigate the cardioprotective effects of curculigoside in situ following I/R injury. Secondly, the present study demonstrated that curculigoside inhibited mitochondria-mediated apoptosis by acting on the MPTP. However, other apoptotic signaling pathways, such as death receptor-mediated apoptosis, were not investigated. Therefore, further investigation of the mechanism of action of curculigoside is required.

In conclusion, the present study revealed a previously unknown, at least to the best of our knowledge, cardioprotective effect of curculigoside. The results obtained in the present study may serve as the basis for the development of novel therapeutic agents for MIRI.

Funding

This study was supported by the National Natural Science Foundation of China (grant nos. 81670320 and 81800232) and the Natural Science Foundation of Liaoning Province (grant no. 201602826).

Availability of data and materials

The datasets generated and analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

DJ and NW conceived and designed the experiments. YZ conducted the experiments. YG, YC, and SL participated in the completion of the experiments. YZ and NW analyzed the data. YZ and NW wrote the manuscript. All authors read and approved the final version of this manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of China Medical University and procedures for animals handling and care adhered to the Guide for the Care and Use of Laboratory Animals.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.